Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency

[1]  M. Kloor,et al.  European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender , 2021, The British journal of surgery.

[2]  S. Stevanović,et al.  A vaccine targeting mutant IDH1 in newly diagnosed glioma , 2021, Nature.

[3]  E. Jonasch,et al.  High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  A. Akinkuotu,et al.  Surgical outcomes and survival rates of colon cancer in children and young adults. , 2021, American journal of surgery.

[5]  R. McLendon,et al.  Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy , 2021, Nature communications.

[6]  T. Pugh,et al.  Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis , 2020, JNCI cancer spectrum.

[7]  T. Pons,et al.  Role of POLE and POLD1 in familial cancer , 2020, Genetics in Medicine.

[8]  Raymond Y Huang,et al.  Mechanisms and therapeutic implications of hypermutation in gliomas , 2020, Nature.

[9]  J. Soria,et al.  Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types , 2020, Cancer medicine.

[10]  S. Kopetz,et al.  Colon Cancer in Patients Under 25 Years Old: A Different Disease? , 2020, Journal of the American College of Surgeons.

[11]  D. Su,et al.  Contributions of Age-Related Thymic Involution to Immunosenescence and Inflammaging , 2020, Immunity & Ageing.

[12]  J. Sampson,et al.  Brain immunology and immunotherapy in brain tumours , 2019, Nature Reviews Cancer.

[13]  A. Regev,et al.  Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma , 2019, Nature Medicine.

[14]  Honglang Li,et al.  Metastatic patterns and survival outcomes in patients with stage IV colon cancer: A population‐based analysis , 2019, Cancer medicine.

[15]  David C. Smith,et al.  Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab , 2019, JAMA oncology.

[16]  E. Sokol,et al.  Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. , 2019 .

[17]  Jan Baumbach,et al.  Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology , 2019, Bioinform..

[18]  D. Cortez.  Replication-Coupled DNA Repair. , 2019, Molecular cell.

[19]  Ahmet Zehir,et al.  Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response , 2019, Science.

[20]  Ash A. Alizadeh,et al.  Determining cell-type abundance and expression from bulk tissues with digital cytometry , 2019, Nature Biotechnology.

[21]  Trevor J Pugh,et al.  An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE) , 2019, Journal of Immunotherapy for Cancer.

[22]  P. Wen,et al.  Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma , 2018, Nature Medicine.

[23]  Trevor J Pugh,et al.  CapTCR-seq: hybrid capture for T-cell receptor repertoire profiling. , 2018, Blood advances.

[24]  M. Tsao,et al.  Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective. , 2018, Current oncology.

[25]  Ville Mustonen,et al.  The repertoire of mutational signatures in human cancer , 2018, Nature.

[26]  R. Schulte‐Hermann,et al.  Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma , 2018, Scientific Reports.

[27]  A. Naranjo,et al.  Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials , 2017, Cancer.

[28]  K. Cole,et al.  Comprehensive Analysis of Hypermutation in Human Cancer , 2017, Cell.

[29]  M. Nielsen,et al.  NetMHCpan-4.0: Improved Peptide–MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data , 2017, The Journal of Immunology.

[30]  P. Sorensen,et al.  Assessment of programmed death‐ligand 1 expression and tumor‐associated immune cells in pediatric cancer tissues , 2017, Cancer.

[31]  Gad Getz,et al.  Analysis of somatic microsatellite indels identifies driver events in human tumors , 2017, Nature Biotechnology.

[32]  T. Cloughesy,et al.  Detection of immune responses after immunotherapy in glioblastoma using PET and MRI , 2017, Proceedings of the National Academy of Sciences.

[33]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[34]  Zoltan Szallasi,et al.  MuPeXI: prediction of neo-epitopes from tumor sequencing data , 2017, Cancer Immunology, Immunotherapy.

[35]  Jedd D. Wolchok,et al.  T-cell invigoration to tumour burden ratio associated with anti-PD-1 response , 2017, Nature.

[36]  T. Hida,et al.  Risk of tumor flare after nivolumab treatment in patients with irradiated field recurrence , 2017, Medical Oncology.

[37]  Roland Eils,et al.  Complex heatmaps reveal patterns and correlations in multidimensional genomic data , 2016, Bioinform..

[38]  M. Yalon,et al.  Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors , 2016, Journal of Neuro-Oncology.

[39]  V. Seshan,et al.  FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing , 2016, Nucleic acids research.

[40]  Nicolai J. Birkbak,et al.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.

[41]  F. Cunningham,et al.  The Ensembl Variant Effect Predictor , 2016, bioRxiv.

[42]  Joseph Kaplinsky,et al.  Robust estimates of overall immune-repertoire diversity from high-throughput measurements on samples , 2016, Nature Communications.

[43]  B. Taylor,et al.  deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution , 2016, Genome Biology.

[44]  E. Mardis,et al.  pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens , 2016, Genome Medicine.

[45]  Mikhail Shugay,et al.  MiXCR: software for comprehensive adaptive immunity profiling , 2015, Nature Methods.

[46]  C. Mackall,et al.  Going back to class I: MHC and immunotherapies for childhood cancer , 2015, Pediatric blood & cancer.

[47]  Roland Arnold,et al.  Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers , 2015, Nature Genetics.

[48]  C. Hawkins,et al.  High frequency of mismatch repair deficiency among pediatric high grade gliomas in Jordan , 2014, International journal of cancer.

[49]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[50]  Richard A. Moore,et al.  Derivation of HLA types from shotgun sequence datasets , 2012, Genome Medicine.

[51]  Wendy S. W. Wong,et al.  Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..

[52]  A. McKenna,et al.  Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.

[53]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[54]  U. Dirksen,et al.  Risk of recurrence and survival after relapse in patients with Ewing sarcoma , 2011, Pediatric blood & cancer.

[55]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[56]  Gonçalo R. Abecasis,et al.  The variant call format and VCFtools , 2011, Bioinform..

[57]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[58]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[59]  Ash A. Alizadeh,et al.  SUPPLEMENTARY NOTE , 1879, Botanical Gazette.

[60]  D. Gfeller,et al.  EPIC: A Tool to Estimate the Proportions of Different Cell Types from Bulk Gene Expression Data. , 2020, Methods in molecular biology.

[61]  Ash A. Alizadeh,et al.  Profiling Tumor Infiltrating Immune Cells with CIBERSORT. , 2018, Methods in molecular biology.

[62]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[63]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[64]  Claude-Alain H. Roten,et al.  Fast and accurate short read alignment with Burrows–Wheeler transform , 2009, Bioinform..

[65]  T. Watts,et al.  TNF/TNFR family members in costimulation of T cell responses. , 2005, Annual review of immunology.